AKT1 and breast carcinoma: Several preclinical studies have shown that the PI3K–AKT–mTOR pathway plays a key role in mediating resistance to ET in breast cancer, and the concept of targeting the PI3K–AKT–mTOR pathway to augment ET has now been proven in clinical settings.